Loading company…
Yuyao Biotech develops drug candidates and platforms for cancer and other diseases.
Established in Shanghai in 2020, Yuyao Biotech develops drugs, including EP4 receptor small molecule antagonists for advanced cancers. Its antagonists have entered phase I clinical trials. The company reported more than 50 employees and over 20 invention patents. In November 2025, it raised venture funding from Xiangjiang Xincheng Fund.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in